Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Medically reviewed by Archana Sharma, DO Key Takeaways Active surveillance, or watchful waiting, is often recommended for people with slow-growing CLL who do not have symptoms.Targeted therapies, such ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Staging means finding out how far cancer has spread in your body. Different types of leukemia are assessed in different ways, and some are not staged. There is no standard staging system that applies ...

MLR may be a useful marker for assessing activity and progression in chronic lymphocytic leukemia (CLL). Patients with CLL had significantly lower MLR values compared to healthy individuals, with ...

The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of ...

Medically reviewed by Archana Sharma, DO Key Takeaways Early symptoms of leukemia include headaches, fatigue, and fever. In advanced stages, you may experience red skin spots and frequent infections.

A key question you’ll likely have after chronic lymphocytic leukemia (CLL) treatment is how well it worked. At that point, your care team may mention “remission,” which means there’s no sign of cancer ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

Targeted therapies may improve survival in these patients by concurrently managing immune dysregulation and the leukemic clone.

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) The ...